stockrowSyndax Pharmaceuticals, Inc.
SNDXSyndax Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $172.4 million, up 627.8% from fiscal 2024.
- Revenue
- +81.6%
- EPS
- +21.4%
- Free cash flow
- +61.4%
- Total debt
- +71.1%
Quarter to September 2026, against a year earlier
Follow SNDX
Alert me
Syndax Pharmaceuticals, Inc. (SNDX) Return on invested capital
Syndax Pharmaceuticals, Inc.'s return on invested capital over the twelve months to 30 September 2026 was −83.4%, down 83.4 percentage points from fiscal 2025 (0.00%). Over the past ten years it has ranged from −434.2% (fiscal 2024) to 0.00% (fiscal 2025) — the current reading is the highest in ten years. That is below the Biotechnology industry median of 0.00% and below the Healthcare sector median of 0.00%.
Return on invested capital, annual
Embed this chart
Annual newest first
| Period | Return on invested capital | Change (points) |
|---|---|---|
| FY2025 | 0.00% | 434.21 |
| FY2024 | −434.2% | (434.21) |
| FY2023 | 0.00% | 0.00 |
| FY2022 | 0.00% | 0.00 |
| FY2021 | 0.00% | 0.00 |
| FY2020 | 0.00% | 0.00 |
| FY2019 | 0.00% | 0.00 |
| FY2018 | 0.00% | 0.00 |
| FY2017 | 0.00% | 0.00 |
| FY2016 | 0.00% | 0.00 |
Against its own ten years
Return on invested capital against peers
| Company | Return on invested capital |
|---|---|
| RIGL Rigel Pharmaceuticals, Inc. compare | 13.7% |
| LTGO Latigo Biotherapeutics Inc compare | 0.00% |
| OBX Obsidian Therapeutics, Inc compare | 0.00% |
| ALMS Alumis Inc. compare | 0.00% |
| SLDB Solid Biosciences Inc. compare | 0.00% |
| GLUE Monte Rosa Therapeutics, Inc. compare | 0.00% |
| SNDX Syndax Pharmaceuticals, Inc. | −83.4% |
| LXRX Lexicon Pharmaceuticals, Inc. compare | −109.1% |
| DNA Ginkgo Bioworks Holdings, Inc. compare | −155.8% |
| Biotechnology industry median | 0.00% |
| Healthcare sector median | 0.00% |
| Market median | 0.00% |
What Return on invested capital is
Return on Invested Capital shows how much after-tax operating profit a company earns on the money its lenders and shareholders have put in.
TTM: (Operating Income × 0.625) ÷ (Shareholders Equity (Total) (latest quarter) + Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter) − Cash & Short Term Investments (latest quarter)); Annual: (Operating Income × 0.625) ÷ (Shareholders Equity (Total) + Long Term Debt (Total) + Current Part of Debt − Cash & Short Term Investments)